Phaseline

Companies › ARTHEx Biotech

ARTHEx Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATX-01
miR-23b inhibitor (synthetic single-stranded oligonucleotide/anti-miR)
MIR-23BPhase 1Myotonic Dystrophy 1Jul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06300307ATX-01Phase 1Myotonic Dystrophy 1NeurologyJul 2027

Targets

MIR-23B (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.